US Stock Market Movement: Moderna Surges on October 20 Driven by Melanoma Phase III Data, Cancer Vaccine Progress, and Target Price Upgrade

Moderna's Surge on October 20 – Analysis

Keywords: Phase III melanoma data, cancer vaccine, target price increase

1. During the trading session on October 20, as the stock price surged, it was announced that data from the Phase III melanoma study for the personalized cancer therapy developed jointly by Moderna and Merck would be released at the ESMO Congress on October 24. The study compares postsurgical intismeran autogene combined with Keytruda versus Keytruda alone; previous five-year Phase IIb data showed that the combination therapy reduced the risk of recurrence or death by 49%.

2. On October 19, Oddo BHF raised Moderna’s target price from $170 to $251; Bank of America Global Research increased its target price from $200 to $220 on the same day.

(Disclaimer: This content is a summary generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)